AGIO
Bearish signalScored 2026-10-24 Drivers: Congress, trend, fundamentals. Moteurs : Congrès, tendance, fondamentaux.
Research, not advice.
À propos
Agios Pharmaceuticals, Inc.
- Nom
- Agios Pharmaceuticals, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $2.2B
- Employés
- 540
- PDG
- Brian Goff
- Site web
- https://www.agios.com
- Marché
- BCRXIRONMIRMPHARPTCTRARE
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Decouvert par les declarations du Congres
- Insiders
- —
- Total bought
-
—
Avg buy (VWAP, 90d window) —
- Total sold
-
$989,042
Avg sell (VWAP, 90d window) $30.92 vs last close $36.85 (+19.2%)
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
$914,400 of that total is under a Rule 10b5-1 plan. It is shown here and left out of the score.
- Last activity
- —
- Liquidity
- Liquid $43,659,550/day · 20d vol
- Last synced
-
2026-10-26 21:10:04
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-10-22 | Gheuens Sarah | Sell · S | 500 | $37.52 | $18,760 | Form 4 |
| 2026-10-21 | Gheuens Sarah | Sell · S | 1,489 | $37.53 | $55,882 | Form 4 |
| 2026-08-04 | Gheuens Sarah | Sell · S · 10b5-1 | 30,000 | $30.48 | $914,400 | Form 4 |
Sales marked 10b5-1 are scheduled in advance and don't count toward the Quorum score. Les ventes marquées 10b5-1 sont planifiées à l'avance et ne pèsent pas dans le score Quorum.
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
| Date | Member | Side | Amount range | Filing |
|---|---|---|---|---|
| 2026-08-20 | Gilbert Cisneros | Buy | $1,001 - $15,000 | Filing |
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2026-08-20 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2026-03-03 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-12-11 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-04-17 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2025-01-29 | Gilbert Cisneros | Purchase | $1,001 - $15,000 |
| 2024-01-24 | Josh Gottheimer | Purchase | $1,001 - $15,000 |
Signal
Bearish signalScored 2026-10-24 Drivers: Congress, trend, fundamentals. Moteurs : Congrès, tendance, fondamentaux.
AGIO presents a deeply conflicted profile: a strong liquidity ratio (score 85) is undermined by persistent cash burn, negative free cash flow, and an alarming fundamentals trend score of 15, signaling structural…
The first sentence of the analysis written for AGIO on 2026-10-24 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Pulls against a bullish reading. Selling cluster — sale value, no purchase value
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Congress Supports a bullish reading. 2 purchase disclosures year to date
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Unavailable or mixed. Current ratio 11.46 · operating margin -874% — readings disagree
Suggested stop 32.31, nearest stored support minus 0.5 ATR(12.3% under the last close). Reward/risk to the next stored resistance is 1.59. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Recent news
- 2026-10-08 Agios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8:00 a.m. ET CAMBRIDGE, Mass., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced the company will host a conference call and live webcast on Thursday, November 5, 2026, at 8:00 a.m.
- 2026-10-06 AGIO Stock Sinks 29% in Three Months: Here''s What You Need to Know Agios faces a narrower growth path as tebapivat setbacks shift focus to mitapivat sales, SCD expansion and regulatory prospects.
- 2026-10-02 Agios'' Growth Story Hinges on Mitapivat''s Commercial Expansion AGIO''s mitapivat is driving growth as Aqvesme gains traction, while an SCD opportunity and pipeline setbacks increase its importance.
- 2026-09-04 Bank of New York Mellon Corp Invests $7.37 Million in Agios Pharmaceuticals, Inc. $AGIO Bank of New York Mellon Corp purchased a new position in Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 198,685 shares of the biopharmaceutical company''s stock, valued at approximately $7,373,000. Bank of
- 2026-08-20 Agios Pharmaceuticals: Indication Stacking Is Creating A Commercial Flywheel Agios is leveraging mitapivat''s commercial platform across PK deficiency, thalassemia, and potentially sickle cell disease to build a durable rare-disease franchise. Thalassemia launch drove Q2 2026 mitapivat revenue to $44.7M, up 259% YoY, with strong payer coverage and operational leverage emerging. AGIO''s $965M cash position supports pipeline expansion and mitigates near-term dilution risk ahead of the November 1, 2026, PDUFA for mitapivat in sickle cell.
- 2026-08-13 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO NEW YORK, Aug. 13, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. ("Agios" or the "Company") (NASDAQ: AGIO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
- 2026-08-13 Assenagon Asset Management S.A. Has $3.86 Million Stock Holdings in Agios Pharmaceuticals, Inc. $AGIO Assenagon Asset Management S.A. lifted its stake in Agios Pharmaceuticals, Inc. (NASDAQ: AGIO) by 54.8% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 103,955 shares of the biopharmaceutical company''s stock after acquiring an additional 36,802 shares during the quarter. Assenagon
- 2026-08-11 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO NEW YORK, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. (“Agios” or the “Company”) (NASDAQ: AGIO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
- 2026-08-06 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO NEW YORK, Aug. 6, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. ("Agios" or the "Company") (NASDAQ: AGIO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
- 2026-08-04 INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Agios Pharmaceuticals, Inc. - AGIO NEW YORK, Aug. 04, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Agios Pharmaceuticals, Inc. (“Agios” or the “Company”) (NASDAQ: AGIO). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Market snapshot
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 78.7% | 88.6% | 64.6% | 88.0% | 0.0% | |
| Ebit Margin | -765.9% | 1967.1% | -1312.6% | -1627.8% | 0.0% | |
| Ebitda Margin | -756.3% | 1982.6% | -1287.9% | -1567.7% | 0.0% | |
| Operating Profit Margin | -873.9% | -1166.5% | -1459.5% | -2732.1% | 0.0% | |
| Pretax Profit Margin | -765.9% | 1967.1% | -1312.6% | -1627.8% | 0.0% | |
| Continuous Operations Profit Margin | -764.0% | 1845.9% | -1312.6% | -1627.8% | 0.0% | |
| Net Profit Margin | -764.0% | 1845.9% | -1312.6% | -1627.8% | 0.0% | |
| Bottom Line Profit Margin | -764.0% | 1845.9% | -1312.6% | -1627.8% | 0.0% | |
| Current Ratio | 11.460 | 11.898 | 12.270 | 13.297 | 17.789 | |
| Quick Ratio | 11.059 | 11.558 | 11.990 | 13.161 | 17.789 | |
| Solvency Ratio | -3.915 | 5.558 | -2.740 | -1.619 | 11.073 | |
| Cash Ratio | 1.084 | 0.940 | 1.298 | 2.224 | 3.395 | |
| Price To Earnings Ratio | -3.823 | 2.771 | -3.518 | -6.638 | -5.168 | |
| Price To Earnings Growth Ratio | 0.024 | -0.010 | -0.071 | 0.198 | -0.151 | |
| Forward Price To Earnings Growth Ratio | 0.024 | -0.010 | -0.071 | 0.198 | -0.151 | |
| Price To Earnings Diluted Ratio | -3.823 | 2.823 | -3.518 | -6.638 | -5.168 | |
| Price To Earnings Diluted Growth Ratio | 0.024 | -0.010 | -0.071 | 0.198 | -0.151 | |
| Price To Book Ratio | 1.323 | 1.211 | 1.528 | 1.398 | 1.538 | |
| Price To Sales Ratio | 29.207 | 51.145 | 46.205 | 108.040 | 0.000 | |
| Price To Free Cash Flow Ratio | -4.182 | -4.768 | -4.172 | -4.894 | -4.810 | |
| Price To Operating Cash Flow Ratio | -4.231 | -4.788 | -4.186 | -4.971 | -4.878 | |
| Debt To Assets Ratio | 0.031 | 0.034 | 0.077 | 0.069 | 0.068 | |
| Debt To Equity Ratio | 0.034 | 0.037 | 0.089 | 0.078 | 0.075 | |
| Debt To Capital Ratio | 0.033 | 0.036 | 0.082 | 0.072 | 0.070 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.087 | 1.079 | 1.155 | 1.125 | 1.113 | |
| Working Capital Turnover Ratio | 0.062 | 0.044 | 0.035 | 0.016 | 0.000 | |
| Operating Cash Flow Ratio | -4.537 | -4.804 | -4.357 | -4.941 | -6.808 | |
| Operating Cash Flow Sales Ratio | -6.903 | -10.681 | -11.038 | -21.733 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.012 | 1.004 | 1.003 | 1.016 | 1.014 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -9.276 | -6.841 | -4.112 | -3.613 | -4.195 | |
| Capital Expenditure Coverage Ratio | -86.417 | -231.360 | -296.358 | -63.405 | -70.949 | |
| Dividend Paid And Capex Coverage Ratio | -86.417 | -231.360 | -296.358 | -63.405 | -70.949 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -3.742 | 2.553 | -3.541 | -6.652 | -5.416 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 78.7% | ▼-9.9% | ▲14.7% |
| Ebit Margin | -765.9% | ▼-2733.0% | ▼-418.1% |
| Ebitda Margin | -756.3% | ▼-2739.0% | ▼-430.4% |
| Operating Profit Margin | -873.9% | ▲292.6% | ▲372.5% |
| Pretax Profit Margin | -765.9% | ▼-2733.0% | ▼-418.1% |
| Continuous Operations Profit Margin | -764.0% | ▼-2609.9% | ▼-392.3% |
| Net Profit Margin | -764.0% | ▼-2609.9% | ▼-392.3% |
| Bottom Line Profit Margin | -764.0% | ▼-2609.9% | ▼-392.3% |
| Current Ratio | 11.460 | ▼-0.438 | ▼-1.883 |
| Quick Ratio | 11.059 | ▼-0.499 | ▼-2.052 |
| Solvency Ratio | -3.915 | ▼-9.473 | ▼-5.586 |
| Cash Ratio | 1.084 | ▲0.145 | ▼-0.704 |
| Price To Earnings Ratio | -3.823 | ▼-6.594 | ▼-0.548 |
| Price To Earnings Growth Ratio | 0.024 | ▲0.034 | ▲0.026 |
| Forward Price To Earnings Growth Ratio | 0.024 | ▲0.034 | ▲0.026 |
| Price To Earnings Diluted Ratio | -3.823 | ▼-6.646 | ▼-0.558 |
| Price To Earnings Diluted Growth Ratio | 0.024 | ▲0.034 | ▲0.026 |
| Price To Book Ratio | 1.323 | ▲0.111 | ▼-0.077 |
| Price To Sales Ratio | 29.207 | ▼-21.938 | ▼-17.712 |
| Price To Free Cash Flow Ratio | -4.182 | ▲0.585 | ▲0.383 |
| Price To Operating Cash Flow Ratio | -4.231 | ▲0.557 | ▲0.380 |
| Debt To Assets Ratio | 0.031 | ▼-0.003 | ▼-0.025 |
| Debt To Equity Ratio | 0.034 | ▼-0.003 | ▼-0.029 |
| Debt To Capital Ratio | 0.033 | ▼-0.003 | ▼-0.026 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.087 | ▲0.008 | ▼-0.025 |
| Working Capital Turnover Ratio | 0.062 | ▲0.018 | ▲0.030 |
| Operating Cash Flow Ratio | -4.537 | ▲0.267 | ▲0.552 |
| Operating Cash Flow Sales Ratio | -6.903 | ▲3.778 | ▲3.168 |
| Free Cash Flow Operating Cash Flow Ratio | 1.012 | ▲0.007 | ▲0.002 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Coverage Ratio | -9.276 | ▼-2.436 | ▼-3.669 |
| Capital Expenditure Coverage Ratio | -86.417 | ▲144.942 | ▲63.281 |
| Dividend Paid And Capex Coverage Ratio | -86.417 | ▲144.942 | ▲63.281 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -3.742 | ▼-6.295 | ▼-0.383 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $1.58B | $1.87B | $1.24B | $1.54B | $1.99B | |
| Enterprise value | $1.53B | $1.85B | $1.22B | $1.48B | $1.88B | |
| EV / Sales | 28.30x | 50.62x | 45.60x | 104.28x | 0.00x | |
| EV / Op. cash flow | -4.10x | -4.74x | -4.13x | -4.80x | -4.62x | |
| EV / Free cash flow | -4.05x | -4.72x | -4.12x | -4.72x | -4.55x | |
| EV / EBITDA | -3.74x | 2.55x | -3.54x | -6.65x | -5.42x | |
| Net debt / EBITDA | 0.12x | -0.03x | 0.05x | 0.24x | 0.30x | |
| Current ratio | 11.46x | 11.90x | 12.27x | 13.30x | 17.79x | |
| Income quality | 0.90x | -0.58x | 0.84x | 1.33x | 1.14x | |
| Graham number | — | $85 | — | — | $113 | |
| Graham net-net | $13 | $14 | $12 | $12 | $15 | |
| Tax burden | 99.8% | 93.8% | 100.0% | 100.0% | -450.1% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Working capital | $859.8M | $884.4M | $765.9M | $770.1M | $1.00B | |
| Invested capital | $901.1M | $939.0M | $835.7M | $858.3M | $1.11B | |
| Return on assets | -31.8% | 40.5% | -37.6% | -18.7% | 111.6% | |
| Operating ROA | -31.9% | -32.7% | -36.0% | -29.1% | -33.0% | |
| Return on tangible assets | -31.8% | 40.5% | -37.6% | -18.7% | 111.6% | |
| Return on equity | -34.6% | 43.7% | -43.4% | -21.1% | 124.2% | |
| Return on invested capital | -38.2% | -25.0% | -44.3% | -32.7% | -27.2% | |
| Return on capital employed | -38.9% | -26.9% | -45.0% | -33.1% | -27.5% | |
| Earnings yield | -26.2% | 36.1% | -28.4% | -15.1% | 80.8% | |
| Free cash flow yield | -23.9% | -21.0% | -24.0% | -20.4% | -20.8% | |
| Capex / Op. cash flow | -1.2% | -0.4% | -0.3% | -1.6% | -1.4% | |
| Capex / Depreciation | 83.4% | 29.8% | 15.1% | 57.0% | 62.1% | |
| Capex / Sales | 8.0% | 4.6% | 3.7% | 34.3% | 0.0% | |
| SG&A / Sales | 333.7% | 429.6% | 447.0% | 854.4% | 0.0% | |
| R&D / Sales | 618.9% | 825.5% | 1077.1% | 1965.7% | 0.0% | |
| Stock comp / Sales | 97.3% | 117.4% | 166.9% | 346.2% | 0.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 71d | 41d | 38d | 57d | 0d | |
| Days payables outstanding | 581d | 1459d | 376d | 3988d | 325d | |
| Operating cycle | 1114d | 2461d | 771d | 1876d | 0d | |
| Cash conversion cycle | 533d | 1003d | 395d | -2112d | -325d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years